ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "ba17c34a-c7b6-4219-b0a5-bcbb2883ab90"}, "_deposit": {"id": "2016189", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2016189"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02016189", "sets": ["1642838220226", "1642838412624"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "[\u7dcf\u8aac\uff3d\u30d1\u30eb\u30d7\u30ed\u9178\u306e\u85ac\u7269,\u4ee3\u8b1d\u52d5\u614b : \u50ac\u5947\u602a\u4e88\u9632\u306e\u89b3\u70b9\u304b\u3089", "subitem_1551255648112": "ja"}, {"subitem_1551255647225": "Pharmacokinetics and metabolism of valproate : In relation to prevention of valproate teratogenicity", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u8fd1\u85e4, \u6bc5", "creatorNameLang": "ja"}]}, {"creatorNames": [{"creatorName": "Kondo, Tsuyoshi", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "ja", "subitem_1522651041219": "\u7409\u7403\u533b\u5b66\u4f1a"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "valproate"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "teratogenicity"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "polypharmacy"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "pharmacokinetics"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "metabolism"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Pharmacokinetics and metabolism of valproate (VPA) has been discussed in relation to the risk and prevention of VPA teratogenicity. Prospective epidemiological studies have shown that high VPA dosages (\u22671000 mg/day) and high VPA concentrations (\u2267 70$ \\mu $g/ml) together with VPA polypharmacy (especially coadministration with enzyme-inducing antiepileptic drugs) are regarded as clinical risk factors for increased VPA teratogenicity. An animal experiment has also shown that high peak concentration after single dosing of VPA during the early stage of pregnancy correlates well with the incidence of neural tube defects. All of these risk factors enhance metabolic conversion from VPA to its toxic metabolite, 2-propy1-4-pentenoic acid (4-en). On the other hand, the use of slow-release formulation of valproate (VPA-SR) results in reduced formation of 4-en as well as decreased diurnal fluctuations in VPA concentrations. These pharmacokinetic and metabolic alterations by using VPA-SR may be helpful in reducing VPA teratogenicity. We therefore recommend that high VPA dosages, high VPA concentrations and VPA polypharmacy should be avoided in epileptic women of childbearing age. Conventional VPA, when used in these subjects, should be replaced with VPA-SR before pregnancy to diminish the risk of VPA teratogenicity.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "ja", "subitem_1522300316516": "\u7409\u7403\u533b\u5b66\u4f1a"}, {"subitem_1522300295150": "en", "subitem_1522300316516": "Ryukyu Medical Association"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "jpn"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1346888X"}, {"subitem_1522646500366": "ISSN", "subitem_1522646572813": "0289-1530"}, {"subitem_1522646500366": "NCID", "subitem_1522646572813": "AN10369445"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "ja", "subitem_1522650091861": "\u7409\u7403\u533b\u5b66\u4f1a\u8a8c = Ryukyu Medical Journal"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueNumber": "3", "bibliographicPageEnd": "77", "bibliographicPageStart": "71", "bibliographicVolumeNumber": "23"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "v23p71.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2016189/files/v23p71.pdf"}, "version_id": "9c3d7f33-7aae-4ad6-84a7-260eb58d4aea"}]}, "item_title": "[\u7dcf\u8aac\uff3d\u30d1\u30eb\u30d7\u30ed\u9178\u306e\u85ac\u7269,\u4ee3\u8b1d\u52d5\u614b : \u50ac\u5947\u602a\u4e88\u9632\u306e\u89b3\u70b9\u304b\u3089", "item_type_id": "15", "owner": "1", "path": ["1642838220226", "1642838412624"], "permalink_uri": "http://hdl.handle.net/20.500.12000/0002016189", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2010-07-02"}, "publish_date": "2010-07-02", "publish_status": "0", "recid": "2016189", "relation": {}, "relation_version_is_last": true, "title": ["[\u7dcf\u8aac\uff3d\u30d1\u30eb\u30d7\u30ed\u9178\u306e\u85ac\u7269,\u4ee3\u8b1d\u52d5\u614b : \u50ac\u5947\u602a\u4e88\u9632\u306e\u89b3\u70b9\u304b\u3089"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. 琉球医学会
  3. 琉球医学会誌
  4. 23巻3号
  1. 部局別インデックス
  2. その他

[総説]パルプロ酸の薬物,代謝動態 : 催奇怪予防の観点から

http://hdl.handle.net/20.500.12000/0002016189
http://hdl.handle.net/20.500.12000/0002016189
46d51252-03fb-4e41-8748-2f10eb60e3ad
名前 / ファイル ライセンス アクション
v23p71.pdf v23p71.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2010-07-02
タイトル
タイトル [総説]パルプロ酸の薬物,代謝動態 : 催奇怪予防の観点から
言語 ja
作成者 近藤, 毅

× 近藤, 毅

ja 近藤, 毅

Kondo, Tsuyoshi

× Kondo, Tsuyoshi

en Kondo, Tsuyoshi

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 ja
権利情報 琉球医学会
主題
言語 en
主題Scheme Other
主題 valproate
言語 en
主題Scheme Other
主題 teratogenicity
言語 en
主題Scheme Other
主題 polypharmacy
言語 en
主題Scheme Other
主題 pharmacokinetics
言語 en
主題Scheme Other
主題 metabolism
内容記述
内容記述タイプ Other
内容記述 Pharmacokinetics and metabolism of valproate (VPA) has been discussed in relation to the risk and prevention of VPA teratogenicity. Prospective epidemiological studies have shown that high VPA dosages (≧1000 mg/day) and high VPA concentrations (≧ 70$ \mu $g/ml) together with VPA polypharmacy (especially coadministration with enzyme-inducing antiepileptic drugs) are regarded as clinical risk factors for increased VPA teratogenicity. An animal experiment has also shown that high peak concentration after single dosing of VPA during the early stage of pregnancy correlates well with the incidence of neural tube defects. All of these risk factors enhance metabolic conversion from VPA to its toxic metabolite, 2-propy1-4-pentenoic acid (4-en). On the other hand, the use of slow-release formulation of valproate (VPA-SR) results in reduced formation of 4-en as well as decreased diurnal fluctuations in VPA concentrations. These pharmacokinetic and metabolic alterations by using VPA-SR may be helpful in reducing VPA teratogenicity. We therefore recommend that high VPA dosages, high VPA concentrations and VPA polypharmacy should be avoided in epileptic women of childbearing age. Conventional VPA, when used in these subjects, should be replaced with VPA-SR before pregnancy to diminish the risk of VPA teratogenicity.
内容記述タイプ Other
内容記述 論文
出版者
言語 ja
出版者 琉球医学会
言語
言語 jpn
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1346888X
収録物識別子タイプ ISSN
収録物識別子 0289-1530
収録物識別子タイプ NCID
収録物識別子 AN10369445
収録物名
言語 ja
収録物名 琉球医学会誌 = Ryukyu Medical Journal
書誌情報
巻 23, 号 3, p. 71-77
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-22 04:16:33.281979
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3